YLYongbo Liu

Yongbo Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yongbo Liu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The hepatic immune niche in liver diseases and transplantation: from homeostasis to therapeutic targeting

    by Yunmu Gao, Qianxiao Cheng, Hongyuan Liu, Jiaqi Song, Bingran Wang, Aiwei Zhou, Tao Zhou, Jianjun Zhu, Zhipeng Zong, Zhicong Zhao, et al.

    The liver combines continuous exposure to gut-derived antigens and metabolites with immune surveillance and tissue repair. Its immune niche is organized by interactions among sinusoidal endothelial cells, Kupffer cells, recruited leukocytes, and parenchymal and stromal cells. At homeostasis, these interactions support antigen clearance and restrained immune activation. Persistent injury changes antigen presentation, metabolite availability, leukocyte recruitment, and extracellular matrix composition, allowing local immune responses to contribute to continued tissue damage. In chronic viral, steatotic, alcohol-associated, cholestatic, and autoimmune liver diseases, distinct patterns of myeloid activation, lymphocyte dysfunction, cytotoxicity, and fibrogenesis emerge at parenchymal, biliary, and vascular interfaces. Hepatocellular carcinoma (HCC) adds tumor-derived signals that suppress antitumor immunity within a heterogeneous hepatic environment. In liver transplantation, perioperative injury intersects with donor-specific cellular and humoral immunity, with outcomes ranging from controlled donor reactivity to distinct, sometimes overlapping forms of rejection and chronic remodeling. Xenotransplantation further exposes the graft to interspecies antibody, complement, endothelial, and coagulation incompatibilities. In inflammatory liver disease and transplantation, blocking local signals that support pathogenic lymphocyte survival or myeloid activation may reduce continued tissue injury. In HCC, limiting tumor-derived metabolic signals that suppress immune-cell function may instead help restore antitumor responses. Continued recruitment from the circulation may replenish pathogenic populations despite suppression of cells already within the liver, making cellular recruitment an additional potential target. Effective treatment must therefore interrupt the processes sustaining injury while preserving antimicrobial defense, antitumor surveillance, graft regulation, and tissue repair.

  • EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance

    by Yongbo Liu, Bingran Wang, Di Sun, Aiwei Zhou, Zimeng Cai, Tao Zhou, Sen Yang, Qi Pan, Yunmu Gao, Jiaqi Song, et al.


  • tRNA m1A modification regulates cholesterol biosynthesis to promote antitumor immunity of CD8+ T cells

    by Shan Miao, Hao Li, Xiaohan Song, Yongbo Liu, Gaoyang Wang, Chen Kan, Youqiong Ye, Ru-Juan Liu, Hua-Bing Li

    Activation of CD8+ T cells necessitates rapid metabolic reprogramming to fulfill the substantial biosynthetic demands of effector functions. However, the posttranscriptional mechanisms underpinning this process remain obscure. The transfer RNA (tRNA) N1-methyladenine (m1A) modification, essential for tRNA stability and protein translation, has an undefined physiological function in CD8+ T cells, particularly in antitumor responses. Here, we demonstrate that the tRNA m1A “writer” gene Trmt61a enhances the tumor-killing capacity of CD8+ T cells by regulating cholesterol biosynthesis. Deletion of Trmt61a in CD8+ T cells leads to a compromised tumor-killing function in both in vivo and in vitro assays. Mechanistically, tRNA m1A promotes antitumor immunity in CD8+ T cells by enhancing the translation of ATP citrate lyase, a key enzyme for cholesterol biosynthesis. Cholesterol supplementation rescues the impaired tumor-killing function and proliferation of TRMT61A-deficient CD8+ T cells. Our findings highlight tRNA m1A modification as a regulatory checkpoint in cholesterol metabolism in CD8+ T cells, suggesting potential novel strategies for cancer immunotherapy.


  • Open Access

    Comparison of Pathogenicity of Different Infectious Doses of H3N2 Canine Influenza Virus in Dogs

    by Yongbo Liu, Cheng Fu, Gang Lu, Jie Luo, Shaotang Ye, Jiajun Ou, Xiangbin Wang, Haibin Xu, Ji Huang, Liyan Wu, et al.

    The canine influenza virus (CIV) outbreaks have raised concerns as they pose a threat to the health of dogs. The successful construction of a canine influenza (CI) infection model is essential to study the CIV. Here we investigated the pathogenicity of different infectious doses of H3N2 CIV in Beagle dogs. Thirty-seven healthy Beagle dogs were used in the experiment and were infected with 103, 104, 105, and 106 50% egg-infectious doses (EID50). Compared to the dogs in the other three groups, those in the 106 EID50 group presented with obvious clinical symptoms, high virus titer, and typical pathological changes. Considering the ensemble of clinical scores, body temperature, virus shedding, lung lesions, pathological section scores, and visceral virus titers, we determined that 106 EID50 is the minimum infectious dose for the Beagle infection model. The other three infectious doses had almost no clinical symptoms. These results indicate that 106 EID50 is the minimum infectious dose of H3N2 CIV that can cause obvious clinical manifestations and pathological changes associated with CI in Beagle dogs. The theoretical framework developed in this research will guide the establishment of an infection model of CIV for future research.